Chronic, painful tendon and ligament disorders such as tendinopathy are frequent in both athletic and less active or inactive individuals. Patients are commonly referred to general and sports medicine practitioners, but the tools for treatment are limited and too often not efficient. One of the evolving treatment options for tendinopathy includes the use of PRP (Platelet Rich Plasma, a concentrated blood plasma that contains high levels of platelets) extracted from the patients’ blood, which serves as a storage for healing-promoting growth factors. However, PRP usually displays poor retention of the platelets at the injury site and their fast dissipation may limit the effect of the growth factors.
Vergenix™STR is a soft tissue repair matrix that was designed for mixing with PRP to form a scaffold with delayed degradation and enhanced retention to the injury site, in order to enable a localized, prolonged therapeutic effect.
Vergenix™STR is intended for treatment of tendinopathy.
VergenixSTR is distributed in Europe by Arthrex, and is marketed together with the Arthrex ACP® kit, under the brand ACP® Tendo. More information regarding product procurement can be found in Arthrex’s website: www.arthrex.com/orthobiologics/arthrex-acp-tendo.